Abortion is more than a debate about conscientious objection.

Pettinger M, et al. Women’s Health Initiative Investigators. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA 2003; 290: 1739–1748. 28 Archer DF. The effect of the duration of progestin use on the occurrence of endometrial cancer in postmenopausal women. Menopause 2001; 8: 245–251. 29 de Vries CS, Bromley SE, Thomas H, Farmer RD. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK. Drug Saf 2005; 28: 241–249. 30 Archer DF, Hendrix S, Ferenczy A, Felix J, Chris Gallagher J, Rymer J, et al., for the THEBES Study Group. Tibolone Histology of the Endometrium and Breast Endpoints Study: design of the trial and endometrial histology at baseline in postmenopausal women. Fertil Steril 2007; [Epub 2 June 2007]. 31 Newcomb PA, Trentham-Dietz A. Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 2003; 14: 195–201. 32 Greiser CM, Greiser EM, Doren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. Hum Reprod Update 2007; [Epub 27 June 2007]. 33 Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women. J Natl Cancer Inst 2002; 94: 497–504. MWS, HRT and female malignancy/View from primary care